MDMA interactions with pharmaceuticals and drugs of abuse
Expert Opinion on Drug Metabolism & Toxicology – March 31, 2020
Source: OpenAlex
Summary
MDMA, widely used as a recreational drug, poses significant risks when combined with other substances. Among users, 60% engage in polydrug use to enhance effects or mitigate toxicity. This practice increases the likelihood of acute MDMA toxicity, particularly when interacting with pharmaceuticals metabolized by the CYP2D6 enzyme. Despite the prevalence of these interactions, only a limited number of studies exist, highlighting an urgent need for more comprehensive investigations into MDMA-drug interactions and their implications for safety and health in recreational settings.
Abstract
Introduction: MDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, has become one of the most widely used recreational psychostimulant drugs in the world. Among recreational ecstasy/MDMA users, polydrug use is a phenomenon whose common purpose is to experience the synergistic effect of the combined drugs, moderate MDMA effects, prevent potential toxicity, enhance a high or come down from a high from other drugs, or simply to treat existing medical conditions. Thus, MDMA-drug interactions (MDMA-DIs) lead to a higher risk of acute and life-threatening MDMA toxicity.Areas covered: This article provides an overview of the MDMA-DIs with pharmaceuticals and drugs of abuse. In addition, available evidence is summarized along with clinical recommendations. Finally, the increasing importance of MDMA-DIs is highlighted.Expert opinion: There is a reduced number of published MDMA-DIs studies and scarce clinically significant MDMA-DIs documented in the literature. Experimental evidence points out the relevance of MDMA-DI's when MDMA is co-administered with pharmaceuticals that are metabolized by the CYP2D6 due to MDMA inhibitory action and in the case of repeated MDMA administration (MDMA-MDMAIs).